A COMPARATIVE CLINICAL-TRIAL OF 2 DIFFERENT REGIMENS OF ARTEMETHER PLUS MEFLOQUINE IN MULTIDRUG-RESISTANT FALCIPARUM-MALARIA

Citation
J. Karbwang et al., A COMPARATIVE CLINICAL-TRIAL OF 2 DIFFERENT REGIMENS OF ARTEMETHER PLUS MEFLOQUINE IN MULTIDRUG-RESISTANT FALCIPARUM-MALARIA, Transactions of the Royal Society of Tropical Medicine and Hygiene, 89(3), 1995, pp. 296-298
Citations number
15
Categorie Soggetti
Public, Environmental & Occupation Heath","Tropical Medicine
ISSN journal
00359203
Volume
89
Issue
3
Year of publication
1995
Pages
296 - 298
Database
ISI
SICI code
0035-9203(1995)89:3<296:ACCO2D>2.0.ZU;2-H
Abstract
Plasmodium falciparum in Thailand is highly resistant to available ant imalarial drugs. Artemether, a derivative of artemisinin, is a promisi ng compound currently used to cope with this situation but the course of treatment has to be at least 5 d. An effective short treatment cour se of this drug is possible when used in combination with mefloquine. We now report a trial of different regimens of the combination artemet her/mefloquine. Fifty-seven male Thai patients, admitted to the Bangko k Hospital for Tropical Diseases, were allocated at random to receive oral artemether 300 mg as an initial dose, followed by either the stan dard dose of mefloquine (750 mg) at 24 h or a higher dose of mefloquin e (750 mg at 24 h, then 500 mg at 30 h). Patients were followed up in hospital for 42 d. Two patients, both in the high dose mefloquine grou p, were excluded as they failed to attend for follow-up. All patients had a rapid initial response to treatment with median parasite clearan ce times of 37 and 40 h, median fever clearance times of 33.5 and 30.5 h, and cure rates of 75 and 96% (P = 0.0248), for the standard and hi gh doses of mefloquine respectively. No serious adverse effect was fou nd; mild and transient dizziness, nausea, vomiting and diarrhoea were noted in half of the patients in each group. The results suggest that a 30 h short course of artemether plus mefloquine at high dose should be used in areas with documented mefloquine resistance.